Vinva Investment Management Ltd Grows Holdings in Halozyme Therapeutics, Inc. $HALO

Vinva Investment Management Ltd boosted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 30.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 5,512 shares of the biopharmaceutical company’s stock after purchasing an additional 1,300 shares during the period. Vinva Investment Management Ltd’s holdings in Halozyme Therapeutics were worth $287,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wealth Preservation Advisors LLC acquired a new position in Halozyme Therapeutics in the 1st quarter valued at about $32,000. SVB Wealth LLC purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth approximately $33,000. Employees Retirement System of Texas acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $34,000. Brooklyn Investment Group grew its position in Halozyme Therapeutics by 1,558.1% in the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 670 shares during the last quarter. Finally, Asset Management One Co. Ltd. acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at $98,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on HALO shares. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. Benchmark raised their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. The Goldman Sachs Group lifted their price target on Halozyme Therapeutics from $54.00 to $56.00 and gave the company a “neutral” rating in a research note on Tuesday, November 18th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. Seven investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $75.10.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $71.39 on Friday. The stock has a market cap of $8.39 billion, a price-to-earnings ratio of 16.34, a price-to-earnings-growth ratio of 0.35 and a beta of 1.18. Halozyme Therapeutics, Inc. has a fifty-two week low of $46.26 and a fifty-two week high of $79.50. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. The business has a fifty day moving average of $69.25 and a 200-day moving average of $63.85.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. The firm had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm’s revenue for the quarter was up 22.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.27 earnings per share. As a group, analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $50,721,994.47. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Nicole Labrosse sold 2,227 shares of Halozyme Therapeutics stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total transaction of $173,594.65. Following the completion of the transaction, the chief financial officer owned 22,079 shares in the company, valued at approximately $1,721,058.05. This trade represents a 9.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 110,227 shares of company stock worth $8,028,955. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.